Results 171 to 180 of about 16,509 (232)

Updating the potentially inappropriate medication (PIM)-China criteria for 2024: a Delphi consensus study for improved medication safety in older adults. [PDF]

Int J Clin Pharm
Xing X, Wang K, Wang Z, Li X, Liu J, Liu C, Qiu Y, Yan S, Dong X, Zhang L.   +9 more
europepmc   +1 more source

Analysis of Upper Gastrointestinal Adverse Events Associated with Oral Anticoagulants and Potential Drug Interactions with Cardiovascular Drugs: Exploratory Study Using FDA Adverse Event Reporting System. [PDF]

Pharmaceuticals (Basel)
Cheon S, Park J, Oh D, Kim YS, Chung JE.
europepmc   +1 more source

Impacts on Postoperative Bleeding of Surgery for Head and Neck Malignancies While Continuing Antithrombotic Agents. [PDF]

Int Arch Otorhinolaryngol
Ushiro K, Asato R, Ishida H, Chikugo C, Ito Y, Tsuji T, Tsuji J.   +6 more
europepmc   +1 more source

Editorial: NETosis, complement activation and pattern recognition at the intersection of inflammatory disorders. [PDF]

Front Immunol
Das N, Rai G, Madan T, Kishore U.
europepmc   +1 more source

Heteroaromatic swapping in aromatic ketones. [PDF]

Nat Commun
Nakahara H, Shirai R, Nishimoto Y, Yokogawa D, Yamaguchi J.   +4 more
europepmc   +1 more source

Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology. [PDF]

BMC Pharmacol Toxicol
Li P, Cao M, Liu L, Chen L, Liang S, Wang Y.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Synthesis and structure-activity relationships of ticlopidine derivatives and analogs as inhibitors of ectonucleotidase CD39.

Bioorganic chemistry (Print), 2023
Ticlopidine is an antithrombotic prodrug of the thienotetrahydropyridine family. For platelet inhibition it has to undergo oxidative ring-opening by cytochrome P450 enzymes.
Chunyang Bi, Laura Schäkel, Salahuddin Mirza, Katharina Sylvester, J. Pelletier, Sang-Yong Lee, Thanigaimalai Pillaiyar, J. Sévigny, C. Müller   +8 more
semanticscholar   +1 more source

Ticlopidine

Reactions Weekly, 2019
semanticscholar   +3 more sources

Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide.

Minerva Cardioangiologica : a Journal on Cardiovascular Pathophysiology, Clinical Medicine and Therapy, 2019
BACKGROUND The aim of this study is to evaluate the use of Aspirin, Pycnogenol®, ticlopidine, and sulodexide to reduce the incidence of new RTV (retinal vein thrombosis) after a first episode.
G. Belcaro, M. Dugall, Hugh D Bradford, M. Cesarone, B. Feragalli, C. Gizzi, R. Cotellese, Shu Hu, P. Rodriguez, M. Hosoi   +9 more
semanticscholar   +1 more source